Top Markets
#1 Nesa Nesa +824.35%
#2 Cortex Cortex +68.57%
#3 Merlin's Seal BTC Merlin's Seal BTC +45.55%
#4 QuantixAI QuantixAI +23.90%
#5 EXOD EXOD +22.78%
#6 Pons Pons +19.27%
#7 Instadapp Instadapp +16.92%
#8 BSquared Network BSquared Network +16.73%
#9 Wrapped STX (Velar) Wrapped STX (Velar) +15.44%
#10 The Black Bull The Black Bull +13.69%
Coin of the day
Nesa Nesa
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Shanghai Junshi Biosciences Co., Ltd. Shanghai Junshi Biosciences Co., Ltd.

Shanghai Junshi Biosciences Co., Ltd.

688180
Classifica tra le azioni #3524
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise... Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical enterprise dedicated to the research, development, and marketing of innovative therapeutic agents. Operating within the People's Republic of China, their focus spans critical medical areas such as oncology, metabolic diseases, autoimmune disorders, neurological conditions, and infectious diseases. Among its principal offerings is JS001, commercialized as TUOYI. This recombinant humanized anti-PD-1 monoclonal antibody has received approval for a broad spectrum of cancer indications, including various forms of melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple-negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. Beyond TUOYI, Junshi Biosciences boasts a robust pipeline of investigational drugs. These include UBP1211, a biosimilar of Humira, targeting conditions like rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody aimed at hyperlipidemia; and UBP1213, a recombinant humanized anti-BLyS monoclonal antibody in injectable form. Further developments encompass JS501, a biosimilar to Avastin; JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, identified as a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. The company has also established strategic collaborations. Notably, it partners with Eli Lilly and Company on the co-development of therapeutic antibodies intended for the prevention and treatment of COVID-19, the illness caused by the SARS-CoV-2 novel coronavirus. Additionally, an alliance with Coherus Biosciences, Inc. facilitates the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Founded in 2012, Shanghai Junshi Biosciences Co., Ltd. maintains its corporate headquarters in Shanghai, People's Republic of China.
Prezzo delle azioni
$5.07
Capitalizzazione di mercato
$5.17B
Variazione (1 giorno)
-0.71%
Variazione (1 anno)
-19.68%
Paese
CN
Scambia Shanghai Junshi Biosciences Co., Ltd. (688180)

Categoria

Healthcare
Ricavi di Shanghai Junshi Biosciences Co., Ltd. (688180)
Ricavi nel Aug 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Shanghai Junshi Biosciences Co., Ltd., i ricavi attuali dell'azienda (TTM) sono pari a 0. Nel 2026, l'azienda ha registrato ricavi di 0 uguale a i ricavi dell'anno 2026, che erano pari a 0. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Shanghai Junshi Biosciences Co., Ltd. da 2026 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
Non abbastanza dati per le date fornite.
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH